Related Experiment Video

Updated: Jun 30, 2026

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 19, 2013

Implementation of "clinical sequencing" in cancer genome medicine in Japan

Takashi Kohno1,2

  • 1Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.

Cancer Science
|December 30, 2017
PubMed

Insights

Actionable mutations identified through next-generation sequencing (NGS) guide cancer treatment. Japan is implementing NGS-based gene panel tests and clinical practice guidelines to advance cancer genome medicine.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Diagnostics

Background:

  • Actionable mutations in cancer-associated genes are crucial for selecting effective therapeutic strategies.
  • Clinical sequencing using next-generation sequencing (NGS) of tumor DNA provides diagnostic and prognostic information.
  • NGS facilitates the identification of targeted therapies and immune checkpoint blockade treatments.

Purpose of the Study:

  • To assess the implementation and value of clinical sequencing in Japan.
  • To align with international standards for molecular-guided cancer therapy.
  • To facilitate the adoption of cancer genome medicine in Japan.

Main Methods:

  • Review of investigations by Japanese academic institutions on clinical sequencing feasibility.
  • Analysis of consensus clinical practice guidance issued by Japanese cancer societies for NGS-based gene panel tests.
  • Comparison with established tumor-profiling multiplex gene panel practices in the USA.

Main Results:

  • Detailed investigations into the feasibility and value of clinical sequencing have been conducted in Japan.
  • Consensus clinical practice guidance for NGS-based gene panel tests has been established by Japanese cancer societies.
  • These efforts indicate a strong move towards integrating cancer genome medicine into clinical practice in Japan.

Conclusions:

  • Clinical sequencing and NGS-based gene panel tests are becoming integral to oncology in Japan.
  • The development of guidelines and feasibility studies supports the advancement of cancer genome medicine.
  • These initiatives will enhance personalized therapeutic approaches for cancer patients in Japan.
Keywords:
actionable mutationcancer genome medicineclinical sequencingimplementationinsurance reimbursement

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Related Concept Videos

Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Maxam-Gilbert Sequencing01:05

Maxam-Gilbert Sequencing

In the same year as the discovery of the Sanger sequencing method, another group of scientists, Allan Maxam and Walter Gilbert, demonstrated their chemical-cleavage method for DNA sequencing. The Maxam-Gilbert method relies on using different chemicals that can cleave the DNA sequence at specific sites, the separation of resulting DNA fragments of variable size using electrophoresis, and deciphering the DNA sequence from the resulting gel bands.
Challenges of the Maxam-Gilbert Method
The...